Evidence map›Paper›PMID 40852369›Full record

ReviewFrontiers in medicine2025

Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system.

Xuan Xiao, You Nie, Yiping Leng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xuan XiaoDepartment of Laboratory Medicine, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Changsha, China.
You NieDepartment of Laboratory Medicine, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Changsha, China.
Yiping LengHengyang Medical School, The Affiliated Changsha Central Hospital, Changsha Tuberculosis Research Institute, University of South China, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sialic acid is a common terminal monosaccharide residue on glycan chains, and desialylation of glycoproteins is considered an important biological signal. In the liver and other cell types, asialoglycoprotein receptor 1 (ASGR1) specifically recognizes and binds to exposed galactose or N-acetylgalactosamine (Gal/GalNAc) residues on desialylated glycoproteins, and activates downstream signaling pathways through receptor-mediated endocytosis (RME), thereby playing important roles in various physiological and pathological processes such as immune regulation, viral infection, hepatocellular carcinoma progression, and lipid metabolism. In addition, ASGR1 is regarded as a key target for liver-specific drug delivery. This review systematically describes the molecular structure and physiological functions of ASGR1, its roles in pathological processes, and its potential functions in extrahepatic tissues. It provides essential background information for a comprehensive understanding of ASGR1 and offers novel insights into future research directions.

Indexed as

ASGR1glycoprotein recognitionhepatocellular carcinomalipid metabolismtargeted drug deliveryviral infection

Identifiers

PMID40852369
PMCPMC12367805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.